Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

25.43 +0.08 (+0.32%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks

March 13, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference

March 05, 2025

Via ACCESS Newswire

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

March 05, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds ↗

February 28, 2025

Amphastar's Q4 sales grew 20% to $186.5M, missing estimates. Primatene MIST surpassed $100M in annual sales, while Baqsimi saw strong growth.

Via Benzinga

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024

February 27, 2025

Via ACCESS Newswire

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024

November 06, 2024

Via ACCESSWIRE

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024

August 07, 2024

Via ACCESSWIRE

Amphastar: Earnings Miss, Margins Drop ↗

February 28, 2025

Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results.

Via The Motley Fool

Topics Earnings

Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 Sales Targets, Stock Drops 12.1%

February 27, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.7% year on year to $186.5 million. Its non-GAAP profit of $0.92 per...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow

February 26, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.

Via StockStory

Top 2 Health Care Stocks That May Rocket Higher This Month ↗

February 21, 2025

Via Benzinga

Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks

February 21, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025

February 20, 2025

Via ACCESS Newswire

Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest

February 19, 2025

Via StockStory

Topics Artificial Intelligence Intellectual Property

NASDAQ:AMPH is an undervalued gem with solid fundamentals. ↗

February 18, 2025

AMPHASTAR PHARMACEUTICALS IN is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:AMPH showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks

February 14, 2025

Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season.

Via StockStory

Topics Artificial Intelligence Intellectual Property

ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group

February 13, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

This Ollie's Bargain Outlet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

February 04, 2025

Via Benzinga

Investors should take notice of NASDAQ:AMPH—it offers a great deal for the fundamentals it presents. ↗

January 27, 2025

AMPHASTAR PHARMACEUTICALS IN has caught the attention as a great value stock. NASDAQ:AMPH excels in profitability, solvency, and liquidity, all while being very reasonably priced.

Via Chartmill

Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 08, 2025

Via ACCESSWIRE

NASDAQ:AMPH is an undervalued gem with solid fundamentals. ↗

January 06, 2025

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) appears to be flying under the radar despite its strong fundamentals.

Via Chartmill

Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

November 26, 2024

Via ACCESSWIRE

Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

November 13, 2024

Via ACCESSWIRE

Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade ↗

October 15, 2024

Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.

Via Investor's Business Daily

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability ↗

September 06, 2024

JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris.

Via Benzinga

Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference

August 28, 2024

Via ACCESSWIRE

AMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024 ↗

August 07, 2024

AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024

July 31, 2024

Via ACCESSWIRE

7 Biotech Stocks to Buy on the Dip: June 2024 ↗

June 24, 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.